Ionis Pharmaceuticals, Inc. (IONS) Dividend History

Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics. Founded in 1989, the company focuses on using antisense technology to develop medicines for various diseases, including neurological, rare, and severe conditions. Ionis is known for its innovative approach to addressing unmet medical needs through gene-silencing strategies.

2855 Gazelle Court, Carlsbad, CA, 92010
Phone: (760) 931-9200
Website: https://www.ionispharma.com

Dividend History

Ionis Pharmaceuticals, Inc. currently does not pay dividends

Company News

  • Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

    Biogen will present scientific data on lecanemab and tau-targeted therapies at the 2025 Alzheimer's Association International Conference, showcasing long-term clinical trial results and potential new treatment approaches for Alzheimer's disease.

    GlobeNewswire Inc.
    Featured Companies: BIIB
  • Ionis Pharma Beats Expectations for Q4

    Ionis Pharmaceuticals, a leader in RNA-targeted drug discovery, reported better-than-expected revenue and a smaller-than-expected loss in Q4 2024. The company's recent product launches, including Wainua and Tryngolza, contributed to the positive results, and it plans to continue investing in its pipeline and product launches in 2025.

    The Motley Fool
  • How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?

    AstraZeneca reported strong Q2 results, beating estimates for earnings and sales. The company's key drugs like Tagrisso, Ultomiris, Farxiga, and Calquence performed well, while Lynparza and Imfinzi sales were slightly weak. AstraZeneca raised its sales and earnings growth expectations for the year, citing a strong first-half performance.

    Zacks Investment Research
  • Leerink Partners upgrades Ionis stock on key asset commercialization - Investing.com

    Leerink Partners upgraded Ionis Pharmaceuticals' stock from Market Perform to Outperform, citing the company's focus on wholly-owned assets like olezarsen and donidalorsen, which are nearing commercialization.

    Investing.com
    Featured Companies: ALNY RARE
  • The Latest Analyst Ratings For Ionis Pharmaceuticals - Benzinga

    Ionis Pharmaceuticals (IONS) has received mixed analyst ratings, with an average 12-month price target of $66.17, up from the previous $58.00. The company's financials show challenges, including a decline in revenue and lower-than-average profitability metrics, which may have contributed to the varied analyst sentiment.

    Benzinga
Page data last updated 07/22/2025 06:18:51 UTC